Managing differentiated thyroid cancer

Recent advances in managing differentiated thyroid cancer

The main clinical challenge in the management of thyroid cancer is to avoid over-treatment and over-diagnosis in patients with lower-risk disease while promptly identifying those patients with more advanced or high-risk disease requiring aggressive treatment. In recent years, novel clinical and molecular data have emerged, allowing the development of new staging systems, predictive and prognost...

The surgical approach to managing differentiated thyroid cancer

In recent decades, our understanding of thyroid cancer has improved significantly with the recognition that differentiated thyroid cancer (DTC) has good survival and oncological outcomes. Along with the recent rise in the detection of otherwise subclinical tumours due to improved diagnostics, there has been much debate on how aggressive one should be when performing thyroid and lymph node surge...

Thyroid hormone replacement one day before 131I therapy in patients with well-differentiated thyroid cancer

Objective: The current study aimed to determine the efficacy of radioiodine-131 (131I) ablation therapy with thyroid hormone replacement one day before 131I administration in patients with well-differentiated thyroid cancer (DTC). Methods: This retrospective study included 29 patients who underwent 131I therapies twice for DTC during 6-12 months.  Since all the patients obviously had residual l...

Differentiated Thyroid Cancer in Asians

In the past two decades, thyroid cancer has rapidly increased around the world, including in Korea [1]. Although the exact cause of this increase is still under debate, cancer screening with high-resolution ultrasound (US) might have led to earlier diagnosis of smaller thyroid cancers [2-4]. However, the increased incidence across all tumor sizes suggests that a higher rate of detection of smal...

Managing newly diagnosed thyroid cancer.